Check back for updates on the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium program.

Designed for clinicians, scientists, and all other members of the cancer care and research community, this three-day meeting focuses on the clinical application of scientific advances in immuno-oncology. At the 2019 Symposium, expert faculty will offer new insights on the application of immunotherapy in lung cancer, genitourinary cancers, melanoma and other skin cancers, breast cancer, and gynecologic cancers. Faculty will also discuss the clinical relevance of immunogenomics, T Cell therapies, cancer vaccines, the microbiome, and promising combination strategies.

Each day of the 2019 program will feature a Keynote Lecture given by world-renowned experts on exciting topics in immuno-oncology including genomic analysis for immunotherapy, the future of the field, and T Cell differentiation and exhaustion.

For members of the cancer care team looking for a foundational understanding of immunology, the Symposium will also feature an early morning “Immunology 201” session.

The meeting will also offer several opportunities for robust networking, discussion, and engagement with faculty members and other attendees. Participants in Networking Roundtable sessions will interact with leaders in the field to discuss research and treatment in all of the disease-sites covered by the educational program. During the Trainee and Early-Career Networking Luncheon, faculty will lead small-group discussions on the clinical application of immuno-oncology specifically tailored for early-career attendees.

7:00 AM-8:15 AM Complimentary Continental Breakfast
7:00 AM-7:00 PM Exhibits Open
7:30 AM-8:15 AM Immunology 201

Mary L. Disis, MD, FASCO
University of Washington
Beyond the Basics

Panel Question and Answer
8:15 AM-10:00 AM Welcome and General Session 1: Immunotherapy in Lung Cancer—Sensitivity-Resistance and New Indications

Roy S. Herbst, MD, PhD, FACP, FASCO—Chair
Yale School of Medicine

Laura Quan Man Chow, MD—Chair
University of Washington

Antoni Ribas, MD, PhD
University of California, Los Angeles

Edward B. Garon, MD, MS
University of California, Los Angeles
PDL1 and Tumor Mutational Burden As Biomarkers for Non-Small Cell Lung Cancer: How Do We Personalize Immunotherapy?

Sukhmani K. Padda, MD
Stanford Cancer Institute
Combination Immunotherapy Approaches: From the Lab to the Clinic

Leora Horn, MD
Vanderbilt University Medical Center
Immuno-Oncology and Small Cell Lung Cancer: Have We Finally Solved the Small Cell Paradox?

Scott J. Antonia, MD, PhD
H. Lee Moffitt Cancer Center & Research Institute
Immuno-Oncology and Early Disease: Moving Immunotherapy to Earlier-Stage Disease—A Chance for Greater Benefit or Cure?

Panel Question and Answer
10:00 AM-10:30 AM Break
10:30 AM-11:30 AM General Session 2: Immunogenomics—Insights into Cancer Immunity From Genomics Data and Methods

Elizabeth A. Mittendorf, MD, PhD—Chair
Dana-Farber/Brigham and Women’s Cancer Center

Benjamin G. Vincent, MD—Chair
UNC Chapel Hill Lineberger Comprehensive Cancer Center

Benjamin G. Vincent, MD
UNC Chapel Hill Lineberger Comprehensive Cancer Center
Advances in Tumor Antigen Prediction From Massively Parallel Sequencing Data

Natalie Vokes, MD, MPhil
Dana-Farber Cancer Institute
Genomic Correlates of Response to Immune Checkpoint Blockade 

Vésteinn Thorsson, PhD
Institute for Systems Biology
Systems Biology Insights on the Immune Subtypes of Cancer

Panel Question and Answer
11:30 AM-1:00 PM Poster Session A
With Complimentary Boxed Lunch
11:30 AM-1:00 PM Trials in Progress Poster Session A
With Complimentary Boxed Lunch
11:45 AM-12:45 PM Networking Roundtables: Community Oncologists
1:00 PM-2:15 PM Oral Abstract Session A
2:20 PM-3:00 PM Keynote Lecture

Genomic Analysis for Immunotherapy

Panel Question and Answer
3:00 PM-3:30 PM Break
3:30 PM-4:55 PM General Session 3: Genetically Engineered T-Cell Therapies

Stephen Gottschalk, MD—Chair
St. Jude Children's Research Hospital

David L. Porter, MD—Chair
University of Pennsylvania

David L. Porter, MD
University of Pennsylvania
Future of CD19-CAR T-Cell Therapy for Lymphoma

Damian J. Green, MD
Fred Hutchinson Cancer Research Center
Targeting Multiple Myeloma with Bcma-CAR T Cells

Gregory L. Beatty, MD, PhD
University of Pennsylvania
CAR Therapy for Cancer of the Pancreas

Kole Roybal, PhD
University of California, San Francisco
Synthetic Biology to Improve CAR T-Cell Therapy

Panel Question and Answer
5:00 PM-6:00 PM Tumor Board: Toxicity Management and Moderating Case Reports

David B. Miklos, MD, PhD—Chair
Stanford University School of Medicine

Laura S. Wood, MSN, OCN, RN—Chair
Cleveland Clinic Taussig Cancer Institute

Marco L. Davila, MD, PhD
H. Lee Moffitt Cancer Center & Research Institute
Overview of CAR Toxicities

Panel Question and Answer

Cytokine Release Syndrome

Panel Question and Answer

Bianca Santomasso, BS, PhD, MD
Memorial Sloan Kettering Cancer Center

Panel Question and Answer
6:00 PM-7:00 PM Poster Session A
Reception With Complimentary Wine and Cheese
6:00 PM-7:00 PM Trials in Progress Poster Session A
Reception With Complimentary Wine and Cheese